Home › Funds › RA CAPITAL MANAGEMENT, L.P. › MNPR
RA CAPITAL MANAGEMENT, L.P. position in MNPR
MONOPAR THERAPEUTICS INC · Health Care
RA CAPITAL MANAGEMENT, L.P. reported holding 667,207 shares of MNPR (MONOPAR THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$61.8M, representing 0.54% of its reported portfolio and ranking #37 among its reported holdings. RA CAPITAL MANAGEMENT, L.P. has disclosed MNPR holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How RA CAPITAL MANAGEMENT, L.P.'s MNPR position evolved
RA CAPITAL MANAGEMENT, L.P. first disclosed a stake in MNPR in Q4 2024 at 511,207 shares (US$11.2M). The position peaked in Q2 2026 at 667,207 shares, worth US$61.8M. Across 7 filings, RA CAPITAL MANAGEMENT, L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 667,207 shares valued at US$61.8M. Notable position changes include a 31% increase in Q4 2025 (shares fell 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 511.21K | $11.25M | New |
| Q1 2025 | 511.21K | $18.61M | Hold |
| Q2 2025 | 511.21K | $18.29M | Hold |
| Q3 2025 | 511.21K | $41.75M | Hold |
| Q4 2025 | 667.21K | $43.57M | Add |
| Q1 2026 | 667.21K | $36.56M | Hold |
| Q2 2026 | 667.21K | $61.78M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MNPR and 13F data
MNPR (MONOPAR THERAPEUTICS INC) is a Health Care company. 84 other funds we track also report a position in MNPR — the largest reported positions include DEERFIELD MANAGEMENT COMPANY, L.P. (US$30.0M), Saturn V Capital Management LP (US$28.9M), Siren, L.L.C. (US$25.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MNPR
- DEERFIELD MANAGEMENT COMPANY, L.P. 323.75K sh · $29.98M · Q2 2026
- Saturn V Capital Management LP 311.98K sh · $28.89M · Q2 2026
- Siren, L.L.C. 270.12K sh · $25.01M · Q2 2026
- ADAR1 Capital Management, LLC 217.59K sh · $20.15M · Q2 2026
- TCG Crossover Management, LLC 203.33K sh · $18.83M · Q2 2026
- Vivo Capital, LLC 90.50K sh · $8.38M · Q2 2026
- Ikarian Capital, LLC 47.86K sh · $4.43M · Q2 2026
- STEMPOINT CAPITAL LP 30.12K sh · $2.79M · Q2 2026
- Ishara Investments LP 12.30K sh · $1.14M · Q2 2026
- Martin Investment Management, LLC 2.33K sh · $215.46K · Q2 2026
More on RA CAPITAL MANAGEMENT, L.P.
FAQ
How long has RA CAPITAL MANAGEMENT, L.P. held MNPR?
RA CAPITAL MANAGEMENT, L.P. has disclosed MNPR holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
What is RA CAPITAL MANAGEMENT, L.P.'s current position in MNPR?
As of Q2 2026, RA CAPITAL MANAGEMENT, L.P. holds 667.21K shares of MNPR (MONOPAR THERAPEUTICS INC), valued at $61.78M, representing 0.54% of its reported portfolio and ranking #37.
Has RA CAPITAL MANAGEMENT, L.P. been buying or selling MNPR?
In the latest 13F filing (Q2 2026), RA CAPITAL MANAGEMENT, L.P. held unchanged its position in MNPR. The position peaked in Q2 2026 at 667.21K shares.
Which other funds hold MNPR?
Other major institutional holders of MNPR include DEERFIELD MANAGEMENT COMPANY, L.P., Saturn V Capital Management LP, Siren, L.L.C., among 84 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.